Pliant Therapeutics reports Q4 2025 net loss of $23.6M; advances PLN-101095 Phase 1b after positive ICI-refractory data

PLIANT THERAPEUTICS, INC.

PLN-101095 Phase 1: 4 responders (1 CR, 3 PR) out of 10 secondary ICI-refractory patients; IFN-γ biomarker correlated with response.
Accelerated development: Phase 1b indication expansion trial initiated for NSCLC, RCC, high TMB; first patient enrollment expected Q2 2026.
Q4 2025 net loss $23.6M vs $49.7M YoY; R&D expense fell to $15.6M from $38.8M due to BEACON-IPF discontinuation.
Cash, equivalents and short-term investments $192.4M; expected to fund operations into second half 2028.
Appointed Minnie Kuo as COO; INTEGRIS-PSC Phase 2 results published in Journal of Hepatology (Jan 2026).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income $23.6 million.

Period: fourth quarter ended December 31, 2025
Net income: $23.6 million
Result: reported results

Exact text from the filing

Net loss was $23.6 million as compared to $49.7 million for the prior-year quarter.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.